<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04308278</url>
  </required_header>
  <id_info>
    <org_study_id>LLB-2019-03</org_study_id>
    <nct_id>NCT04308278</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection</brief_title>
  <acronym>EBVAST</acronym>
  <official_title>Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Labo'Life</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Labo'Life</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Worldwide, 95% of adults are infected with Epstein-Barr Virus (EBV). These infections may&#xD;
      cause different diseases. In most cases, EBV infection is asymptomatic because of a highly&#xD;
      effective host immune response. Some individuals develop infectious mononucleosis (a&#xD;
      self-limiting lymphoproliferative disorder in adolescents and young adults that is considered&#xD;
      to be the primary infection), while others develop chronic fatigue syndrome, EBV-associated&#xD;
      lymphoid, or epithelial malignancies.&#xD;
&#xD;
      Today, there is no available treatment to treat and destroy EBV. The treatment is essentially&#xD;
      symptomatic (treatment of the symptoms and not of the virus itself) with analgesics for pain&#xD;
      for example.&#xD;
&#xD;
      The studied drugs are 2LEBV® and 2LXFS®, from Labo'Life company, and the treatment schema is&#xD;
      the same for the two drugs: it consists in taking the content of one capsule per day,&#xD;
      sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is&#xD;
      taken, capsule 1 of the next blister should be taken on the next day to continue the&#xD;
      treatment.&#xD;
&#xD;
      The duration of treatment will be of 6 months of continuous intake of the content of 1&#xD;
      capsule/day.&#xD;
&#xD;
      The aim of this study is to provide additional information on effectiveness on the 2LEBV® and&#xD;
      2LXFS®in the treatment of EBV chronic and acute infections, and in particular to demonstrate&#xD;
      their effectiveness versus placebo in the reduction of asthenia and other symptoms in EBV&#xD;
      infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2021</start_date>
  <completion_date type="Anticipated">January 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 22, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of the general fatigue scale of the Multidiensional Fatigue Inventory-20 (MFI-20) questionnaire at the end of the treatment.</measure>
    <time_frame>6 months</time_frame>
    <description>Multidiensional Fatigue Inventory-20 (MFI-20) questionnaire. 5 scales. Higher scores means worse outcome.&#xD;
General Fatigue dimension: Minimum value: 4. Maximum Value: 20. Physical fatigue dimension: Minimum value: 4. Maximum Value: 20. Reduced activity dimension: Minimum value: 4. Maximum Value: 20. Reduced motivation dimension: Minimum value: 4. Maximum Value: 20. Mental fatigue dimension: Minimum value: 4. Maximum Value: 20.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the efficacy of the treatment on physical fatigue, reduced activity, reduced motivation and mental fatigue scales on the MFI-20 questionnaire between the 2LEBV® or the 2LXFS®/2LEBV® group versus the placebo group</measure>
    <time_frame>6 months</time_frame>
    <description>Multidiensional Fatigue Inventory-20 (MFI-20) questionnaire. 5 scales. Higher scores means worse outcome.&#xD;
Physical fatigue dimension: Minimum value: 4. Maximum Value: 20. Reduced activity dimension: Minimum value: 4. Maximum Value: 20. Reduced motivation dimension: Minimum value: 4. Maximum Value: 20. Mental fatigue dimension: Minimum value: 4. Maximum Value: 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the efficacy of the treatment on general fatigue and other dimensions of the MFI-20 questionnaire between the 2LEBV® and the 2LXFS®/2LEBV® group versus the placebo group.</measure>
    <time_frame>3 months</time_frame>
    <description>Multidiensional Fatigue Inventory-20 (MFI-20) questionnaire. 5 scales. Higher scores means worse outcome.&#xD;
General Fatigue dimension: Minimum value: 4. Maximum Value: 20. Physical fatigue dimension: Minimum value: 4. Maximum Value: 20. Reduced activity dimension: Minimum value: 4. Maximum Value: 20. Reduced motivation dimension: Minimum value: 4. Maximum Value: 20. Mental fatigue dimension: Minimum value: 4. Maximum Value: 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the efficacy of the treatment on general fatigue and other dimensions of the MFI-20 questionnaire between the 2LEBV® and the 2LXFS®/2LEBV® group versus the placebo group.</measure>
    <time_frame>12 months</time_frame>
    <description>Multidiensional Fatigue Inventory-20 (MFI-20) questionnaire. 5 scales. Higher scores means worse outcome.&#xD;
General Fatigue dimension: Minimum value: 4. Maximum Value: 20. Physical fatigue dimension: Minimum value: 4. Maximum Value: 20. Reduced activity dimension: Minimum value: 4. Maximum Value: 20. Reduced motivation dimension: Minimum value: 4. Maximum Value: 20. Mental fatigue dimension: Minimum value: 4. Maximum Value: 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparisons of the efficacy of the treatment on others symptoms related to EBV infection and their duration between the 2LEBV® and 2LXFS®/2LEBV® group versus the placebo group.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparisons of the efficacy of the treatment on others symptoms related to EBV infection and their duration between the 2LEBV® and 2LXFS®/2LEBV® group versus the placebo group.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the evolution of the lymphocytes typing between the 2LEBV® and 2LXFS®/2LEBV® group versus the placebo group.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: occurence of adverse events (AEs) and severe adverse events (SAEs), considered as related or not to the study drug.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparisons of the efficacy of the treatment on others symptoms related to EBV infection and their duration between the 2LEBV® and 2LXFS®/2LEBV® group versus the placebo group.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>EBV Infection</condition>
  <arm_group>
    <arm_group_label>2LEBV® / 2LXFS®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 months of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 months of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2LEBV® / 2LXFS®</intervention_name>
    <description>The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.</description>
    <arm_group_label>2LEBV® / 2LXFS®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Pré-Inclusion Criteria:&#xD;
&#xD;
          -  Patients, male or female, aged 12 years and older,&#xD;
&#xD;
          -  Patient with fatigue for 1 month or more,&#xD;
&#xD;
          -  Patient with at least two other symptoms among the following: Long-lasting exhaustion&#xD;
             even after light exertion, subfebrile state, fever, loss of appetite, nausea, angina,&#xD;
             conjunctivis, sensitive cervical or axillary lymph nodes, erythematous and swollen&#xD;
             tonsil, headaches, sore throat, myalgia, muscular weakness, arthralgia, splenomegaly,&#xD;
             visual disorders, memory disorders, attention deficit disorders, sleep disorders,&#xD;
             gastrointestinal disorders, breathing disorders, cardiovascular disorders.&#xD;
&#xD;
          -  Patient (and/or parents if necessary) agrees to perform serology for the study,&#xD;
&#xD;
          -  Patient (and/or parents if necessary) agrees to perform lymphocyte typing for the&#xD;
             study during the pre-inclusion visit,&#xD;
&#xD;
          -  Patients (and/or parents if necessary) having the faculties to understand and respect&#xD;
             the constraints of the study,&#xD;
&#xD;
          -  Signature of the Informed Consent Form by the patient (and/or parents if necessary).&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        - Patient who have a positive serology for EBV (IgG and/or IgM positive).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who have received any treatment with the 2LEBV® or 2LXFS®,&#xD;
&#xD;
          -  Patients who have received any homeopathic treatment in the previous 2 months prior to&#xD;
             the study,&#xD;
&#xD;
          -  Patients under immunosuppressive treatment,&#xD;
&#xD;
          -  Patient undergoing treatment for psychiatric disorders,&#xD;
&#xD;
          -  Patients having received immunotherapy or micro-immunotherapy during the last 3&#xD;
             months,&#xD;
&#xD;
          -  Patients with known lactose intolerance,&#xD;
&#xD;
          -  Pregnant or breastfeeding women,&#xD;
&#xD;
          -  Patients who participated in a clinical study in the previous 2-months period,&#xD;
&#xD;
          -  Patients (and/or parents of patients if necessary) who are not sufficiently motivated&#xD;
             to engage on the total study follow-up period, or likely to travel or to move before&#xD;
             the end of the study,&#xD;
&#xD;
          -  Patients with severe immunodeficiency disease requiring long term treatment (*) or&#xD;
             patients under chemotherapy or radiotherapy,&#xD;
&#xD;
          -  Patients under homeopathic or phytotherapy treatment,&#xD;
&#xD;
          -  Patients addicted to or using recreational drugs,&#xD;
&#xD;
          -  Patient under guardianship and/or curatorship, (*) important renal or respiratory&#xD;
             insufficiency, transplanted or grafted patients, HIV/AIDS, terminal cancer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hanène BADRI</last_name>
    <phone>491 39 07 38</phone>
    <phone_ext>+32</phone_ext>
    <email>hanene.badri@labolife.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Aartselaar</city>
        <zip>2630</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilse BUNTINX, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Ilse BUNTINX, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Boortmeerbeek</city>
        <zip>3190</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria-Magdalena HAEMELS, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Maria-Magdalena HAEMELS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Brussels</city>
        <zip>1040</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric BEETH, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Eric BEETH, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private practice</name>
      <address>
        <city>Brussels</city>
        <zip>1040</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vania SIDEROVA</last_name>
    </contact>
    <investigator>
      <last_name>Vania SIDEROVA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan-Jaap HUYSMAN, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Jan-Jaap HUYSMAN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maarteen AVET, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Maarteen AVET, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quirico BLONDA, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Quirico BLONDA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Limal</city>
        <zip>1300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quirico BLONDA, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Quirico BLONDA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Nivelles</city>
        <zip>1400</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Véronique BAUDOUX, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Véronique BAUDOUX, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private practice</name>
      <address>
        <city>Waregem</city>
        <zip>8790</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thijs LONCKE, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Thijs LONCKE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Epstein-Barr Virus Infections</mesh_term>
    <mesh_term>Asthenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

